Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Brookfield Infrastructure Partners enters its October 14 quarterly release with one structural fact towering over everything else: its parent, Brookfield Corporation, holds a 31.5% stake on a Schedule 13D, and that stake is growing.
The parent's position is the defining ownership story here. Brookfield Corporation filed a Schedule 13D/A in July 2026, lifting its disclosed holding from 31.3% to 31.5%, or roughly 208 million units. A 13D filing signals active intent, not passive ownership, and the incremental addition of units through the amendment is the clearest expression of conviction on the register. As with all 13D/G disclosures, the stake is as last reported and holders can move without further filings below the 5% threshold, but at 31.5%, Brookfield Corporation is not close to that line. Capital Research and Management sits at 7.3% as the next largest holder, followed by BMO Asset Management at 5.9%, with a cluster of Canadian institutions filling out the top ten. The ownership base is heavily Canadian, reflecting BIP's listing structure and asset geography.
Short interest is a non-story. At 0.38% of the free float, there is almost no short positioning to speak of. The share count has drifted up roughly 32% over the past month in absolute terms, but from such a low base that the absolute number, around 1.75 million units, barely registers against the float. Borrow conditions are the opposite of stressed: availability is near the maximum the system records, meaning shares to borrow vastly outnumber anything currently lent. The cost to borrow did jump sharply in the most recent session to 1.38%, up from 0.43% three days earlier, though that figure is still modest in absolute terms and the 30-day history shows it has traded as high as 2.7% without any market consequence. Options are similarly unremarkable. The put/call ratio of 0.67 sits barely above its 20-day average of 0.66, a z-score of 0.19, pointing to neither particular hedging demand nor unusual call buying ahead of the print.
The analyst picture is one of constructive drift upward. Most recent moves have been target raises, not rating changes. CIBC kept its Outperformer rating and raised the target to $47 in late July, after an earlier move to $45 in May. Morgan Stanley lifted its Overweight target to $46 in May, having upgraded the stock from Equal-Weight to Overweight in March. Citigroup, maintaining its Neutral rating, lifted its target to $41 from $37 in August. The consensus sits at buy, with five buy ratings against two holds. At $37.10, the stock trades below every major target on the register, with CIBC at $47 and Morgan Stanley at $46 implying meaningful upside. Valuation multiples have been compressing modestly: the PE has pulled back roughly 1.2 points over the past 30 days to 28.7x, while EV/EBITDA has eased from around 22.6x to 22.4x over the same period. The dividend score ranks in the 98th percentile of the ORTEX universe, underscoring BIP's positioning as a yield-oriented vehicle. EPS momentum over 30 days ranks at the 94th percentile, though the 90-day read is softer at the 69th, and the EPS surprise factor at just the 7th percentile suggests the company has historically come in below expectations.
Earnings history adds a note of caution on the 5-day horizon. The most recent print in late September produced a 2% gain on the day and a 7.4% gain over five sessions. The two prints before that, in July, both produced single-day losses of around 2% to 5.5%, followed by 5-day drawdowns of 7.9% to 8.6%. Wikipedia page views for BIP are running at a z-score of 1.85 against the prior 90-day average, pointing to above-normal retail attention in the period through September 20, though this dataset has not been measured to lead BIP's financial results and should be taken as a colour note rather than a signal.
With the October 14 print four days away, what to watch is whether the pattern of post-earnings 5-day weakness reasserts itself, and whether the spread between the current price at $37.10 and the analyst target range of $41 to $47 narrows on the back of the result.
See the live data behind this article on ORTEX.
Open BIP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.